Osprey Medical announced the launch of DyeMINISHTM; a global patient registry to evaluate the ongoing safety and performance of the DyeVertTM Contrast Reduction System during standard clinical use in a real-world patient population. The DyeMINISH registry is a retrospective, large-scale, multi-centre study with the first patient included on May 7, 2019. The registry is designed to enrol up to 10,000 participants and is expected to complete in late 2023. The first patient was included in the DyeMINISH registry at St. Elizabeth Healthcare in Edgewood, Kentucky by Dr. Mark Jordan, an Interventional Cardiologist. St. Elizabeth Healthcare operates five facilities throughout Northern Kentucky and more than 115 primary care and specialty office locations in Kentucky, Indiana and Ohio. A member of the Mayo Clinic Care Network, St. Elizabeth is a mission-based organization committed to improving the health of the communities it serves, providing more than $117 million in uncompensated care and benefit to the community in 2017. The DyeMINISH Registry includes two study cohorts. The Core Study cohort is comprised of patients who underwent coronary or peripheral angiography imaging procedure with the DyeVert System. The Comparative Health Outcomes Sub- Study includes patients undergoing the same procedures without DyeVert that can be matched to a DyeVert Group patient via propensity score matching. The Core Study aims to evaluate the use of imaging dye thresholds, actual imaging dye delivered to the patient and imaging dye saved. The Core Study also aims to evaluate the incidence of adverse events, such as the incidence of CI-AKI, the relationship between imaging dye and CI-AKI and other variables through to 120 days post-procedure. The Comparative Health Outcomes Sub-Study will compare the difference in health outcomes between those patients who received DyeVert versus the no DyeVert control via measures which include kidney function, imaging dye use, and incidence of major cardiac and renal adverse events.